Reports and Insights (R&I) has published a new report titled, “Complex Disease Treatment Market: Opportunity Analysis and Future Assessment 2020 to 2028”
Global Complex Disease Treatment Market, by Disease (Asthma, Diabetes, Epilepsy, Hypertension, Manic Depression, Schizophrenia, Others) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2020 and 2028.
As per the report, complex diseases are diseases that progress in severity and are difficult to treat by drugs. Complex diseases are caused by a combination of genetic, environmental, and lifestyle factors, most of which have not yet been identified. The list of such diseases is long and some of them include congestive heart failure, aneurysm, diabetes, kidney diseases, cancers, congenital defects, scleroderma, Alzheimer's disease, Parkinson's disease, asthma, multiple sclerosis, etc.
Understanding disease causes and drug action at the molecular and systems levels could help to identify combinations of drugs that are more effective than individual drugs alone. Current approaches to complex disease treatment have reached their limits, and medicine now requires new thinking to derive drug discovery and usage. Scientists now know that complex diseases do not obey the standard Mendelian patterns of inheritance. Although associated genes are inherited, genetic factors are only part of risk factors. Hence, understanding gene-environment interactions improve knowledge of complex disease causes, and more efficient treatment can be developed.
Furthermore, Reports and Insights (R&I) Study identifies that complex disease requires complex treatment, and advances in genomics, proteomics, etc. have enabled the discovery of new targeted therapies. Several treatment options now available for the treatment of complex diseases include gene therapy, biologic therapy, chemotherapy, microbiome therapy, targeted therapy, etc. among others.
Understanding of systems-biology has enabled the understanding of complex network underlying many diseases such as heart disease, kidney disease, diabetes, metabolic diseases, and cancers. In the case of cardiovascular diseases, there is most likely a genetic component involved, but the role of comorbidities such as diabetes, kidney disease, etc. is not yet well elucidated.
Hence, the treatment of such a complex disease requires a multidisciplinary approach. Most of the drugs known today for complex disease treatment work at the molecular level. These treatments are propagated across scales of the organization to alter tissue or organ function to cure or relieve disease.
R&I Study identifies some of the key participating players in the complex disease treatment market globally are Regeneron Pharmaceuticals, Novo Nordisk, UCB, Solvay Pharmaceuticals, and Allergan, etc.
Reports and Insights (R&I) is committed to providing deep insights that serve as a creative tool for the client that enables it to perform confidently in the market. At R&I we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with a strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.
Reports and Insights (R&I)
For Sales Queries: firstname.lastname@example.org
For New Topics and Other Info: email@example.com